CD86 and graft versus host disease: To manage chronic GvHD, blocking agents against the most potent T cell costimulation pathway (CD80/CD86), namely, abatacept and belatacept, have been used.68,69 However, targeting CD80/CD86 may lead to undesired inhibition of coinhibitory pathways.